Nycomed sues Glenmark over ANDA for fluticasone lotion
This article was originally published in Scrip
Nycomedhas filed a patent infringement suit in the eastern district court of New York against Glenmark Generics' US subsidiary over the latter's ANDA for fluticasone propionate 0.05% lotion. The product is a generic version of Nycomed's Cutivate lotion, used for inflammatory and pruritic manifestations of atopic dermatitis. Glenmark believes it may be the first applicant to have filed an ANDA for this product with a paragraph IV certification. Glenmark will be entitled to a 180-day marketing exclusivity, should it successfully challenge Nycomed's patent. Cutivate 0.05% lotion reported annual sales of about $33 million in the US, IMS sales data to the end of September show.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.